Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in
combination with Opdivo (nivilumab) for the treatment patients with of metastatic, advanced,
or recurrent solid tumors. All participants will receive open-label AL3818 with nivolumab.
Part 1 consists of a dose finding phase to determine the recommended phase 2 dosage of AL3818
with nivolumab. Part 2 consists of a dose expansion phase, evaluating the safety and efficacy
of the combination in patients cohorts including metastatic, advanced, or recurrent soft
tissue sarcomas, non-small cell lung cancer, and small cell lung cancer.